• Medline’s Q3 2026 adjusted EBITDA rose 12% year over year to $960 million.
• Net IEEPA tariff refund benefits contributed $81 million to adjusted EBITDA in the quarter.
• A share repurchase program of up to $1 billion was authorized in October 2026.
• FY26 organic sales growth guidance increased to 10%–10.5%, from 9%–10%.
• Adjusted EBITDA guidance remained $3.3 billion–$3.4 billion, excluding tariff refund benefits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medline Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.